Eukaryotic Cell
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH

EC Accepts, published online ahead of print on 22 December 2006
This Article
Right arrow Full Text (PDF)
Right arrow Other Versions of this Article:
EC.00290-06v1
6/2/134    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Vargas, R. C.
Right arrow Articles by Sá-Correia, I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vargas, R. C.
Right arrow Articles by Sá-Correia, I.

 Previous Article  |  Next Article 

Eukaryotic Cell doi:10.1128/EC.00290-06
Copyright (c) 2006, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.

The Saccharomyces cerevisiae multidrug resistance transporter, Qdr2 is implicated in potassium uptake, providing a physiological advantage to quinidine stressed cells

Rita C. Vargas, Raúl García-Salcedo, Sandra Tenreiro, Miguel C. Teixeira, Alexandra R. Fernandes, José Ramos, and Isabel Sá-Correia*

IBB - Institute for Biotechnology and Bioengineering, Centre for Biological and Chemical Engineering, Instituto Superior Técnico. Av. Rovisco Pais, 1049-001 Lisboa, Portugal, Departamento de Microbiología, Universidad de Córdoba, Edificio Severo Ochoa, Campus de Rabanales, 14071, Spain

* To whom correspondence should be addressed. Email: isacorreia{at}ist.utl.pt.


   Abstract

The QDR2 gene of Saccharomyces cerevisiae encodes a putative plasma membrane drug:H+ antiporter that confers resistance against quinidine, barban, bleomycin and cisplatin. This work provides experimental evidence of defective K+ (Rb+) uptake in the absence of QDR2. The direct involvement of Qdr2p in K+ uptake is reinforced by the fact that increased K+ (Rb+) uptake due to QDR2 expression is independent of the Trk1p,Trk2p system. QDR2 expression confers a physiological advantage for the yeast cell during the onset of K+ limited growth, either due to a limiting level of K+ in the growth medium or to the presence of quinidine. This drug decreases K+ uptake rate and K+ accumulation in the yeast cell, especially in the {Delta}qdr2 mutant. Qdr2p also helps to sustain the decrease of intracellular pH in quinidine stressed cells in growth medium at pH 5.5, by indirectly promoting H+ extrusion affected by the drug. The results are consistent with the hypothesis that Qdr2p may also couple K+ movement with substrate(s) export, presumably with quinidine. Other clues to the biological role of QDR2 in the yeast cell come from two additional lines of experimental evidence. First, QDR2 transcription is activated under nitrogen (NH4+) limitation or when the auxotrophic strain examined enters stationary phase due to leucine limitation, this regulation being dependent on general amino acid control by Gcn4p. Second, the amino acid pool is higher in {Delta}qdr2 cells than in wild type cells, indicating that QDR2 expression is, directly or indirectly, involved in amino acids homeostasis.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Appl. Environ. Microbiol. Infect. Immun. J. Bacteriol.
Mol. Cell Biol. Microbiol. Mol. Biol. Rev. ALL ASM JOURNALS
Copyright © 2006 by the American Society for Microbiology.